Kivelna 100 SR Tablet contains Desvenlafaxine 100mg, a serotonin-norepinephrine reuptake inhibitor (SNRI) used primarily in the management of major depressive disorder (MDD). By selectively inhibiting the reuptake of serotonin and norepinephrine, Kivelna 100 SR enhances neurotransmitter activity in the central nervous system, thereby improving mood and alleviating symptoms of depression. The sustained-release formulation ensures a gradual release of the active ingredient, promoting steady plasma levels and improving patient compliance through once-daily dosing. Indicated for adults diagnosed with MDD, Kivelna 100 SR may also be prescribed off-label for anxiety disorders and other mood-related conditions as determined by a healthcare professional. Common adverse effects include nausea, dizziness, insomnia, dry mouth, and increased sweating, which are generally transient and mild to moderate in intensity. Caution is advised in patients with a history of bipolar disorder, seizures, or hypertension, and it should be used under strict medical supervision to monitor for potential serotonin syndrome or suicidal ideation, especially during initial treatment phases. Dose adjustments may be necessary in renal impairment. Kivelna 100 SR should not be abruptly discontinued to avoid withdrawal symptoms. It is essential to follow the prescribing physician’s instructions and report any unusual side effects promptly.